Department of Health · Research & Innovation
DOH IRB Research Registry
The Department of Health has introduced an open research registry platform that serves as an official, centralized registry of research studies reviewed by the Abu Dhabi Health Research and Technology Committee – Institutional Review Board (DOH IRB). It is designed to ensure transparency, accountability, and compliance with applicable regulatory standards, including international best practices such as ICH-GCP.
The registry provides structured access to approved, ongoing, and completed studies, supporting oversight, facilitating ethical research conduct, and promoting data integrity. By enabling controlled access to research information, the platform enhances collaboration, strengthens governance, and contributes to the quality and impact of clinical and health research in Abu Dhabi.
311Registered Studies
311Approved by ADHRTC
93Participating Sites
2025Current Batch
Registered Studies
Click View details on any study to see full information.
| # | Year | DOH Reference | Study Title | Details |
|---|---|---|---|---|
| 1 | 2025 | DOH/ADHRTC/2025/2598 | Next Generation Sequencing Analysis and Profiling for Solid and Hematological Malignancies in Patients of Arab Descent | View details › |
| 2 | 2025 | DOH/ADHRTC/2026/230 | Impact of Medically Supervised Performance-Enhancing Substances on Elite Athletes: A Case Series in a Real- World Setting | View details › |
| 3 | 2025 | DOH/ADHRTC/2025/684 | ARGX-113-2315 A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants with Ocular Myasthenia Gravis | View details › |
| 4 | 2025 | DOH/ADHRTC/2025/1873 | AI at the Bedside: A Qualitative Descriptive Study of Clinical and Critical Thinking for New Clinical Graduates Using the Med42 Language Model in a Long-term Care Setting | View details › |
| 5 | 2025 | DOH/ADHRTC/2025/1157 | Review of Janus Kinase (JAK) Inhibitors efficacy and safety in the Treatment of Rheumatoid Arthritis and Some Autoimmune Skin Diseases in a tertiary hospital in UAE | View details › |
| 6 | 2025 | DOH/ADHRTC/2025/11 | Bronchiolitis in infant and children after the surge of COVID-19: predictors of the severity, escalated care and length of stay. | View details › |
| 7 | 2025 | DOH/ADHRTC/2025/1169 | Brain malformations: Description and correlation of clinical phenotype, neuroimaging findings and genomic/genetic findings in pediatric patients in Tawam Hospital, Al Ain, United Arab Emirates. | View details › |
| 8 | 2025 | DOH/ADHRTC/2025/829 | An Observational Multi center Study to Evaluate Real World Treatment Outcomes of Durvalumab based Regimens in Hepatobiliary Cancers | View details › |
| 9 | 2025 | DOH/ADHRTC2025/1031 | Incidence, Risk Factors and Development of Artificial Intelligence-based Risk Prediction Tool for Cardiovascular Disease in the Emirati Adult Population: a retrospective cohort study | View details › |
| 10 | 2025 | DOH/ADHRTC/2025/1132 | The Erectile Restoration Registry: It MATTERS | View details › |
| 11 | 2025 | DOH/ADHRTC/2025/1030 | Genetic and Clinical profile of women in menopause, premature menopause and primary ovarian insufficiency in the UAE | View details › |
| 12 | 2025 | DOH/ADHRTC/2025/564 | A retrospective review of patients with ISS >12 in the United Arab Emirates | View details › |
| 13 | 2025 | DOH/ADHRTC/2025/1148 | Prevalence of Familial Hypercholesterolemia in Abu Dhabi | View details › |
| 14 | 2025 | DOH/ADHRTC/2025/447 | Reducing the burden of ATTR cardiomyopathy in the UAE. | View details › |
| 15 | 2025 | DOH/ADHRTC/2025/363 | Diabetic Foot Disease and Lower Limb Amputations in the Arab Gulf Region: Burden, Trends, and Gaps in Care | View details › |
| 16 | 2025 | DOH/ADHRTC/2025/384 | The Open Source Imaging Consortium: establishing an international biorepository to accelerate digital biomarker research in fibrotic lung disease | View details › |
| 17 | 2025 | DOH/ADHRTC/2025/1004 | Relaxin measurement in different endometrial preparation approaches for frozen embryo transfer | View details › |
| 18 | 2025 | ADHRTC/2025/3 | Perspectives on the Department of Health's initiative to initiate a pharmacogenomic program and upskill pharmacists. | View details › |
| 19 | 2025 | DOH/ADHRTC/2025/464 | Return of Investment from Tobacco Cessation Services interventions in the Emirate of Abu Dhabi | View details › |
| 20 | 2025 | DOH/ADHRTC/2025/366 | A REGISTRY TO COLLECT CHARACTERISTICS AND OUTCOMES FROM PATIENTS WITH SOLID TUMORS PROFILED WITH A NEXT-GENERATION SEQUENCING TEST (WAYFIND-R) | View details › |
| 21 | 2025 | DOH/ADHRTC/2025/309 | The Effects of Chemotherapy on the Retinal Microvasculature in Breast Cancer Patients in Abu Dhabi, UAE. | View details › |
| 22 | 2025 | DOH/ADHRTC/2025/308 | Towards a Scientific Approach in Disability Awareness and Service Optimization | View details › |
| 23 | 2025 | ADHRTC/2025/7 | Exploring Food Habits and Choices Among Elementary School Students in Abu Dhabi | View details › |
| 24 | 2025 | DOH/ADHRTC/2025/831 | Point prevalence survey study of healthcare-associated infections and antimicrobial use, resistance, and appropriateness in the United Arab Emirates | View details › |
| 25 | 2025 | DOH/ADHRTC/2025/368 | Real-World Effectiveness and Safety of Ofatumumab in patients with Relapsing Multiple Sclerosis: The United Arab Emirates Experience | View details › |
| 26 | 2025 | DOH/ADHRTC/2025/369 | Real- World Data Report: Clinical Burden of Diabetic Macular Edema (DME) in Abu Dhabi, United Arab Emirates (UAE) | View details › |
| 27 | 2025 | DOH/ADHRTC/2025/360 | Integrating Multi-Omics to Uncover Environmental and Biological Drivers of Inflammatory Bowel Disease: A Comparative Study of the UAE and Western Cohorts with Longitudinal Profiling of Unaffected First-Degree Relatives (UAE Epi-IBD Study) | View details › |
| 28 | 2025 | DOH/ADHRTC/2025/467 | Care-for-my-foot: Made in the UAE, AI-Driven Smart in-Shoe Wearables: Towards early remote detection and management of diabetes-related foot disease | View details › |
| 29 | 2025 | DOH/ADHRTC/2025/460 | Mapping Sepsis Progression for Precision Medicine Through Temporal Omics: A Lifespan Approach with AI-Driven Outcome Prediction and Tracking through Novel Biomarking | View details › |
| 30 | 2025 | DOH/ADHRTC/2025/673 | AI for Prevention, Prediction, and Prognosis of Breast, Head and Neck, and Colorectal Cancer | View details › |
| 31 | 2025 | DOH/ADHRTC/2025/566 | Investigating the Role of Gut Microbiome in the Development and Progression of MAFLD in Emirati Children and Adolescents | View details › |
| 32 | 2025 | DOH/ADHRTC/2025/674 | Nursing Education Program based on Case Based Learning to prevent Hospital Acquired pressure injury | View details › |
| 33 | 2025 | DOH/ADHRTC/2025/690 | Investigating the Prevalence of Heavy Metals and their Health and Developmental Correlates in Abu Dhabi Residents | View details › |
| 34 | 2025 | DOH/ADHRTC/2025/691 | Anemia in developing and developed countries, and its impact on healthspan and health economics. | View details › |
| 35 | 2025 | DOH/ADHRTC/2025/364 | Assessing Quality of Life and treatment satisfaction of patients with metastatic Breast Cancer initiated on Ribociclib in routine clinical practice in the Gulf Region | View details › |
| 36 | 2025 | DOH/ADHRTC/2025/575 | Allograft failure after liver transplantation | View details › |
| 37 | 2025 | DOH/ADHRTC/2025/441 | Data analysis of IFHAS and DOH health datasets | View details › |
| 38 | 2025 | DOH/ADHRTC/2025/362 | Evaluation of inter-generational increase in shet burden for participants in UAE EGP cohort. | View details › |
| 39 | 2025 | DOH/ADHRTC/2025/361 | STUDY PROTOCOL FOR ASSESSING THE BURDEN OF RESPIRATORY SYNCYTIAL VIRUS (RSV): The Assessment of Burden of Respiratory Syncytial Virus (RSV) Across Different Age Groups and Risk Factors. | View details › |
| 40 | 2025 | DOH/ADHRTC/2025/449 | Overview of birth outcomes in Abu Dhabi | View details › |
| 41 | 2025 | DOH/ADHRTC/2025/367 | Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT). | View details › |
| 42 | 2025 | DOH/ADHRTC/2025/769 | Longitudinal Multi-Omics and Deep Phenotyping of a large-scale human cohort | View details › |
| 43 | 2025 | DOH/ADHRTC/2025/476 | Assessing Quality of Life and treatment satisfaction of patients with metastatic Breast Cancer initiated on Ribociclib in routine clinical practice in the Gulf Region | View details › |
| 44 | 2025 | DOH/ADHRTC/2025/443 | Characteristics and Outcomes of Pediatric Critical Pertussis in Arab Gulf Region: A Multicenter Cohort | View details › |
| 45 | 2025 | DOH/ADHRTC/2025/462 | Evaluation of Cognitive Function in Multiple Sclerosis (MS) Patients Using the Brief International Cognitive Assessment for MS (BICAMS) at a Multiple Sclerosis Center in Abu Dhabi. | View details › |
| 46 | 2025 | DOH/ADHRTC/2025/548 | Identification of novel Microbiota-based therapeutic strategies for multiple sclerosis in the UAE population | View details › |
| 47 | 2025 | DOH/ADHRTC/2025/448 | MSPhenoMaping: An AI-Driven Framework to Uncover Multiple Sclerosis Characteristics and Risk Factors Through Electronic Health Records | View details › |
| 48 | 2025 | DOH/ADHRTC/2025/446 | Novel target identification using 3D and animal pathophysiologic MS models for effective treatment | View details › |
| 49 | 2025 | DOH/ADHRTC/2025/445 | Self-Energy Harvesting Sensors for Enhanced Monitoring of Multiple Sclerosis (SENSE-MS) | View details › |
| 50 | 2025 | DOH/ADHRTC/2025/463 | NMSS-LLM: The world's First Large Language Model for Multiple Sclerosis | View details › |
| 51 | 2025 | DOH/ADHRTC/2025/765 | Integrating Clinical and Genetic Data to Predict Disease-Modifying Treatment Response in Pediatric MS Using AI Modeling: A Pilot Study | View details › |
| 52 | 2025 | DOH/ADHRTC/2025/465 | Unraveling the Biomolecular Landscape of Multiple Sclerosis: A Multi-Omics Approach to Personalized Treatment | View details › |
| 53 | 2025 | DOH/ADHRTC/2025/914 | Fluid challenge in Intensive Care: a worldwide global inception cohort study The FENICE II study | View details › |
| 54 | 2025 | DOH/ADHRTC/2025/563 | Assessing short-term treatment satisfaction and Quality of Life in patients with Hidradenitis Suppurativa initiated on Secukinumab in routine clinical practice in the United Arab Emirates: ILLUMINATE-HS, a prospective patient survey | View details › |
| 55 | 2025 | DOH/ADHRTC/2025/574 | BURDEN OF DISEASE OF CANCER AND CARDIOVASCULAR DISEASES IN THE UNITED ARAB EMIRATES. | View details › |
| 56 | 2025 | DOH/ADHRTC/2025/438 | Identification of genetic and biochemical markers associated with severe obesity in children and adolescents in the UAE | View details › |
| 57 | 2025 | DOH/ADHRTC/2025/444 | Investigating Genetic and Epigenetic associations with Familial Multiple Sclerosis | View details › |
| 58 | 2025 | DOH/ADHRTC/2025/461 | Forecasting Massive Transfusion: Investigating the Efficacy of the RABT score in a level 2 Trauma Centre | View details › |
| 59 | 2025 | DOH/ADHRTC/2025/466 | Antibiotic Use Prediction, Optimization and SAAR Calculation Support: Developing an Artificial Intelligence/Machine Learning Algorithm from a Real-World Electronic Medical Record System | View details › |
| 60 | 2025 | DOH/ADHRTC/2026/161 | Identifying Genetic Markers for Osteoporosis Among Emirati Females Based on Vitamin D Receptor Variants. Healthpoint Hospital; Khalifa University Center for Biotechnology; National Reference; Laboratory (NRL); Zayed University | View details › |
| 61 | 2025 | DOH/ADHRTC/2025/1029 | Exploring the Genetic Landscape of Autism Spectrum Disorder: Unraveling Etiological Factors, Neurobiological Mechanisms, and Phenotypic Variability. | View details › |
| 62 | 2025 | DOH/ADHRTC/2025/599 | Robust HLA typing across whole-genome sequencing platforms | View details › |
| 63 | 2025 | DOH/ADHRTC/2025/1555 | Exploring the Utilisation of Chatbots (AI-Driven Conversational Agents) for Occupational Health Promotion in Abu Dhabi: An Overview of Current Status, Advantages, Obstacles, and Future Prospects. | View details › |
| 64 | 2025 | DOH/ADHRTC/2025/1599 | An Open-Label, Double-Treatment Group Study toEvaluate the Efficacy and Safety of HumanAllogeneic Bone-Marrow-Derived MesenchymalStromal Cell Product StromaForte Compared withHyaluronic Acid for the Treatment of KneeOsteoarthritis | View details › |
| 65 | 2025 | DOH/ADHRTC/2025/348 | Patients’ Practices to Anti-rheumatic Medications During Fasting Month of Ramadan: A Cross-Sectional Survey followed by Consensus recommendations | View details › |
| 66 | 2025 | DOH/ADHRTC/2025/2285 | A Study to Evaluate the Rejuvenation of the OvaryUsing Exosomes Derived from Human PlacentaMesenchymal Stem Cells (ROSE-2): Phase 1bclinical trial | View details › |
| 67 | 2025 | DOH/ADHRTC/2025/1997 | Single-site, minimal-risk staff survey (no patient involvement; no genetic / pharmaceutical / device components):Exploring the Potential of AI to Bridge Cultural and Linguistic Gaps Among Multicultural Staff in a Long-Term-Care Facility in Abu Dhabi Presented in Meeting#12-2025 on 22-May- 2025.Decision was: Conditional Approved (ethically approved but IS CA) Additional documents received, shared with reviewer and approved & IS approval on 18-8-2025. | View details › |
| 68 | 2025 | DOH/ADHRTC/2025/1337 | A Novel Splicing Homozygous Variant in STXBP2Gene Causes Familial HemophagocyticLymphohistiocytosis Type 5: Case Report andLiterature Review | View details › |
| 69 | 2025 | DOH/ADHRTC/2025/545 | Understanding Referral Patterns of Patients with Rheumatic Diseases to Other Healthcare Professionals in the Gulf Region: A Cross-Sectional Survey to Rheumatologists | View details › |
| 70 | 2025 | DOH/ADHRTC/2025/1477 | A prospective, type I hybrid effectiveness-implementation, open label, randomized study to evaluate the impact of a targeted lipid optimization program on LDL-C control in at-risk adult patients from Abu Dhabi,United Arab Emirates (UAE) with dyslipidemia | View details › |
| 71 | 2025 | DOH/ADHRTC/2025/1557 | A prospective, type I hybrid effectiveness-implementation, open label, randomized study to evaluate the impact of a targeted lipid optimization program on LDL-C control in at-risk adult patients from Abu Dhabi, United Arab Emirates (UAE) with dyslipidemia. | View details › |
| 72 | 2025 | DOH/ADHRTC/2025/1994 | Multi-center study:EGCG and Vitamin D3 for Secondary Prevention of Uterine Fibroids (FATIMA Trial)Presented in Meeting#14-2025 on 18-June- 2025.Decision was: Conditional approval. Additional documents received, shared with reviewer (Dr. Rene) and approved & IS approval on 26-June-2025. | View details › |
| 73 | 2025 | DOH/ADHRTC/2025/1556 | Rapid Diagnosis of Mild Traumatic Brain Injury:Evaluating Blood-Brain Biomarkers in the Emergency Department | View details › |
| 74 | 2025 | DOH/ADHRTC/2025/1883 | Transcutaneous electrical nerve stimulation (TENS) for the management of migraine: A prospective, interventional pilot study comparing the effects of different stimulation frequencies | View details › |
| 75 | 2025 | DOH/ADHRTC/2025/1607 | The Impact of Community Resilience on Diabetes Self-Efficacy, Social Support, and Quality of Life in Adults with Type 2 Diabetes: A Predictive Correlational Study In UAE. | View details › |
| 76 | 2025 | DOH/ADHRTC/2025/1996 | Multi-center & medical device study:Clinical Utility of Stockholm3 in public prostate cancer screening program in Abu Dhabi Presented in Meeting#14-2025 on 18-June- 2025.Decision was: Conditional approval.Additional documents received, shared with reviewer (Dr. Adam & Dr. Saleh) and approved, IS approval on 18-Aug-2025 & Genome Approval with statement. | View details › |
| 77 | 2025 | DOH/ADHRTC/2025/1552 | Assessing Leucocyte Telomeres Length as a novel marker of diabetic kidney disease in Emirati patients with type-2 diabetes mellitus. | View details › |
| 78 | 2025 | DOH/ADHRTC/2025/2000 | Multi-center & Policy Evaluation Study:Identification Design for Evaluating the Health and Economic Impact of Weight-Loss Pharmacotherapy Presented in Meeting#14-2025 on 18-June- 2025.Decision was: Conditional approval.Additional documents received, shared with reviewer (Dr. Wasim & Dr. Khaled) and approved & IS approval on 04-Aug-2025. | View details › |
| 79 | 2025 | DOH/ADHRTC/2025/2004 | Multi-center, Clinical Trial, Pharmaceutical sponsored, Research with genetic material, Research that carries significant or potential risk to human subjects (patients) & Processing of medical data outside UAE for research purpose Study:A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis.Presented in Meeting#15-2025 on 09-July- 2025.Decision was: Conditional approval.Additional documents received, shared with reviewer (Dr. Milos & Dr. Shahrukh) and approved, IS approval & Genome Approval with statement. | View details › |
| 80 | 2025 | DOH/ADHRTC/2025/602 | A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. | View details › |
| 81 | 2025 | DOH/ADHRTC/2025/2003 | Genomics-related research Study:Genetic Molecular background of Prolonged QT syndrome in patients of Al Ain regiondiagnosed in the years beetween 2014 and 2024 Presented in Meeting#15-2025 on 09-July- 2025.Decision was: Conditional approval.Additional documents received, shared with reviewer (Dr. Saleh) and approved, IS approval on 18-8-2025 with Genome Clearance. | View details › |
| 82 | 2025 | DOH/ADHRTC/2025/1747 | Developing a Polygenic Risk Score Model for Type 2 Diabetes Using the Emirati Genome Project | View details › |
| 83 | 2025 | DOH/ADHRTC/2025/1893 | CUPAPE: Chronic Urticaria in Pediatric and Adult Populations: Phenotypes and Endotypes in the UAE. | View details › |
| 84 | 2025 | DOH/ADHRTC/2025/1894 | The Emirates Anaphylaxis Registry: A Nationwide Multi-Center Initiative. | View details › |
| 85 | 2025 | ADHRTC/2025/70 | Cross-sectional survey, not a clinical trial, device, or pharmaceutical study:Burnout and Wellbeing Among Health Professionals Practicing in Abu Dhabi, UAE Presented in Meeting#16-2025 on 24-Jul-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Rene) and approved, IS approval on 24-Oct-2025. | View details › |
| 86 | 2025 | DOH/ADHRTC/2025/130 | Population survey to assess the knowledge, attitudes and practices of Emiratis regarding use of genomic data to generate health insights | View details › |
| 87 | 2025 | DOH/ADHRTC/2025/1870 | A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis. | View details › |
| 88 | 2025 | DOH/ADHRTC/2025/2411 | Use of artificial intelligence, data analysis, computed analysis of EHR data Study:External Validation and Prospective Implementation of AI-Based Predictive Models for Antibiotic Susceptibility of Urine Culture.Presented in Meeting#16-2025 on 24-July-2025.Decision was: Conditionally approved.Additional documents received, shared with the reviewers (Dr. Adam) and approved & IS approval on 01-Oct-2025. | View details › |
| 89 | 2025 | DOH/ADHRTC/2025/1872 | A Genetic Mystery: Novel MODY Gene Variants in UAE | View details › |
| 90 | 2025 | DOH/ADHRTC/2025/1895 | Cooking Classes as a Family-based Intervention for Weight Reduction: Effects on Dietary Quality and Weight Management in Abu Dhabi (United Arab Emirates) | View details › |
| 91 | 2025 | ADHRTC/2025/45 | Genomics-related research Study: Emirati Genome Program Insights in Allele Frequency | View details › |
| 92 | 2025 | DOH/ADHRTC/2025/1867 | Precision Lifestyle Medicine Clinical Intervention Study (Quasi-experimental design): Application of a Precision Lifestyle Medicine Clinical Program for a sample of the IFHAS cohort | View details › |
| 93 | 2025 | ADHRTC/2025/65 | Multi-center study:Statin-associated T2D risk operates independently of LDL-C reduction in individuals with normal baseline glucose levels.Presented in Meeting#17-2025 on 31-July-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Milos) and approved, IS approval & Genome approved. | View details › |
| 94 | 2025 | DOH/ADHRTC/2025/573 | Exploring the Landscape of Childhood-Onset Epilepsy to predict risk factors for poor prognosis in the United Arab Emirates | View details › |
| 95 | 2025 | DOH/ADHRTC/2025/2107 | Needs Assessment Study: Assessing the need for visual aids/interventions in communicating absolute genetic risk during premarital counselling at the Metabolic and Genetics center, Tawam hospital, UAE | View details › |
| 96 | 2025 | DOH/ADHRTC/2025/2492 | Multisite, Retrospective & Cohort study:Effectiveness and Safety of Dupilumab in Pediatric Eosinophilic Esophagitis: A Multicenter StudyPresented in Meeting#17-2025 on 31-Jul-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Adam & Dr. Khaled) and approved & IS approval on 23-Oct-2025. | View details › |
| 97 | 2025 | DOH/ADHRTC/2025/1995 | Cross-Sectional and Computational Study:Identification of HPV genotypes through Whole Genome Sequencing and prediction of possible inhibitors through in silico approachPresented in Meeting#17-2025 on 31-July- 2025.Decision was: Conditional approval.Additional documents received, shared with reviewer (Dr. Wasim & Dr. Milos) and approved & IS approval | View details › |
| 98 | 2025 | DOH/ADHRTC/2025/1991 | Single-Center Study:Comprehensive Analysis of COPD Through Electronic Health Records from A Tertiary Hospital in Abu Dhabi (CLEAR)Presented in Meeting#17-2025 on 30-Jul- 2025.Decision was: Conditional Approval.Additional documents received, shared with reviewer (Dr. Khaled) and approved & IS approval on 13-8-2025. | View details › |
| 99 | 2025 | ADHRTC/2025/60 | Real-world evidence of the association between GLP-1 agonist, GLP1/GIP agonist use and incidence of thyroid, breast, colorectal and pancreatic cancer in Abu Dhabi, UAE: A Retrospective Cohort Study (2016-2025). | View details › |
| 100 | 2025 | DOH/ADHRTC/2025/923 | A retrospective test-negative design study to assess the feasibility of monitoring the effectiveness of seasonal influenza vaccines using sentinel surveillance data in the emirate of Abu Dhabi, 2017-2023 | View details › |
| 101 | 2025 | DOH/ADHRTC/2025/1926 | Prospective Observational Study to Assess Effectiveness and Safety of Tralokinumab in Adolescent Patients with Atopic Dermatitis in United Arab Emirates. | View details › |
| 102 | 2025 | DOH/ADHRTC/2025/1993 | Multi-center study:Stakeholders' perceptions and views of the antenatal education programs in Abu Dhabi hospitals.Presented in Meeting#18-2025 on 13-August- 2025.Decision was: Conditional approval.Additional documents received, shared with reviewer (Dr. Khaled) and approved & IS approval | View details › |
| 103 | 2025 | DOH/ADHRTC/2025/2035 | Impact Evaluation of Public Health Initiatives in Abu Dhabi: Evidence from IFHAS and School Health Screening | View details › |
| 104 | 2025 | DOH/ADHRTC/2025/1920 | Screening and monitoring pre-symptomatic autoimmune type 1 diabetes in gulf countries.“Islet autoantibody early detection in at-risk children/adolescents to predict type 1 diabetes: a cohort study in gulf countries”. | View details › |
| 105 | 2025 | DOH/ADHRTC/2025/2513 | Descriptive cross-sectional observational study involving direct observation and self-reported questionnaires from healthcare workers to assess compliance with hand hygiene protocols:Surveillance of Hand Hygiene Practices in Outpatient Clinics, Its Evaluation, and Audit: A Descriptive StudyPresented in Meeting#18-2025 on 13-Aug-2025.Decision was: Conditionally approved.Additional documents received, shared with the reviewers (Dr. Adam & Dr. Rene) and approved and IS approval | View details › |
| 106 | 2025 | DOH/ADHRTC/2025/2206 | Master protocol of two independent, randomized, double-blind, Phase 3 studies comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis. | View details › |
| 107 | 2025 | DOH/ADHRTC/2025/2507 | Multi-center & Genomics-related research:HOFH, THE INTERNATIONAL CLINICAL COLLABORATORS(HICC) A GLOBAL HOFH DATA -SHARING PLATFORMPresented in Meeting#19-2025 on 27-Aug-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Wasim) approved, IS approval on 22-Oct-2025 and genomic approved. | View details › |
| 108 | 2025 | DOH/ADHRTC/2025/2210 | Experimental drug Fosmanogepix in a Pediatric Dialysis Patient with Dual Fungal Endocarditis: First Reported Co-Infection of Aspergillus flavus and Candida parapsilosis | View details › |
| 109 | 2025 | DOH/ADHRTC/2025/2213 | Reason for hospitalization, health outcomes, management pattern and healthcare utilization among older adults in Abu Dhabi – A retrospective cohort study | View details › |
| 110 | 2025 | DOH/ADHRTC/2025/2411 | Multi-center & Research with use of medical device:BEXA Examination Pilot StudyPresented in Meeting#19-2025 on 27-Aug-2025.Decision was: Conditionally approved.Additional documents received, shared with the reviewers (Dr. Wasim) and approved, IS approval on 08-Oct-2025 and ADHTAC approval Letter with statement | View details › |
| 111 | 2025 | DOH/ADHRTC/2025/2131 | Exploratory Study to Assess Utility of RetiSpec Artificial Intelligence Powered Retinal Imaging Solution in Detecting Amyloid Pathology in United Arab Emirates Nationals with Mild Impairment of Cognition H7I-MC-S035 | View details › |
| 112 | 2025 | DOH/ADHRTC/2025/2406 | Multi-center, Pharmaceutical sponsored & non-interventional study:Urticaria Voices: A survey on patients’ and physicians’ perceptions of chronic urticaria and its treatment-Gulf Region – CLOU064AAE01Presented in Meeting#20-2025 on 10-Sep-2025.Decision was: Conditionally approved.Additional documents received, shared with the reviewers (Dr. Saleh & Dr. Rene) and approved and IS approval | View details › |
| 113 | 2025 | DOH/ADHRTC/2025/2405 | Multi-center, Pharmaceutical sponsored & non-interventional study:Urticaria Voices: A survey on patients’ and physicians’ perceptions of chronic urticaria and its treatment-Gulf Region – CLOU064AAE01Presented in Meeting#20-2025 on 10-Sep-2025.Decision was: Conditionally approved.Additional documents received, shared with the reviewers (Dr. Saleh & Dr. Rene) and approved and IS approval | View details › |
| 114 | 2025 | DOH/ADHRTC/2025/2401 | Multi-center & Pharmaceutical sponsored study:Obesity and Overweight-associated Comorbidities: An Analysis of Electronic Health Record Data on Prevalence, Healthcare Resource Utilization, and Treatment Outcomes in the United Arab EmiratesPresented in Meeting#20-2025 on 10-Sep-2025.Decision was: Conditionally approved.Additional documents received, shared with the reviewers (Dr. Rene & Mr. Anil) and approved and IS approval on 17-Oct-2025. | View details › |
| 115 | 2025 | DOH/ADHRTC/2025/2133 | Harnessing MRI and AI for Gender-Specific ACL Injury Risk Stratification | View details › |
| 116 | 2025 | DOH/ADHRTC/2025/2617 | Pharmaceutical sponsored study:Obesity and Overweight-associated Comorbidities: An Analysis of Electronic Health Record Data on Prevalence, Healthcare Resource Utilization, and Treatment Outcomes in the United Arab Emirate | View details › |
| 117 | 2025 | DOH/ADHRTC/2025/2402 | REAL-WORLD DATA/REAL-WORLD EVIDENCE-BASED CLINICAL RESEARCH:Meaningful Activities with Social Robots: A Case of Older Adults | View details › |
| 118 | 2025 | DOH/ADHRTC/2025/668 | Evaluation of the Breast Cancer Screening Program in Abu Dhabi: A Retrospective Cohort and Qualitative Assessment | View details › |
| 119 | 2025 | DOH/ADHRTC/2025/2408 | Multi-Sites, Single center & low risk prospective clinical research:Prospective Evaluation of Standardized Methods for Telomere Length Measurement in Interstitial Lung Disease (ILD)Presented in Meeting#20-2025 on 10-Sep-2025.Decision was: Conditionally approved.Additional documents received, shared with the reviewers (Dr. Rene) and approved, IS approval on 30-Sep-2025 and Genome clearance. | View details › |
| 120 | 2025 | DOH/ADHRTC/2025/2129 | REal-World Application of Luspatercept in Adults with Transfusion-Dependent beta-Thalassemia in the Middle East (RELATE): A non-interventional retrospective and prospective observational study | View details › |
| 121 | 2025 | DOH/ADHRTC/2025/2847 | Registry (Reduce no-show patients and increase operational efficiency by using AI):Integration of AI in Healthcare Decision-Making Processes: Enhancing Efficiency and Patient OutcomesPresented in Meeting#20-2025 on 10-Sep-2025.Decision was: PendingAdditional documents received, shared with reviewer (Dr. Saleh & Dr. Wasim) and approved & IS approved on 10-Dec-2025. | View details › |
| 122 | 2025 | DOH/ADHRTC/2025/2404 | Genomics-related research:Characterization of Genetic Risks, Genetic Counseling Referrals, and Outcomes for Couples Undergoing IVF with PGT-M and PGT-SR at a Fertility Clinic in the UAEPresented in Meeting#21-2025 on 24-Sep-2025.Decision was: Conditionally approved Additional documents received, shared with the reviewers (Dr. Milos & Dr. Shahrukh) and approved, IS approval and Genome Clearance | View details › |
| 123 | 2025 | DOH/ADHRTC/2026/162 | Genomics-related research:Leveraging the AlphaGenome AI tool to assess the effect of pathogenic variants and germline variants of uncertain significance (VUS) in breast cancer patients | View details › |
| 124 | 2025 | DOH/ADHRTC/2025/2618 | Retrospective Chart Review Study (The study involves utilizing data collected through IFHAS screening program of older adults aged 60 or older):Health Status and Preventive Screening Among Older Emiratis: Insights from the Integrated Framework for Healthy Aging Strategy (IFHAS) | View details › |
| 125 | 2025 | ADHRTC/2025/40 | The United Arab Emirates' Trailblazing Leap in Large-Scale Premarital Genetic Screening | View details › |
| 126 | 2025 | DOH/ADHRTC/2025/912 | Multi-Site & Retrospective cross-section study: Assessing the rational use of antibiotics and clinical outcomes in ICU admitted patients: a retrospective cross-sectional study. | View details › |
| 127 | 2025 | DOH/ADHRTC/2025/2403 | Interventional study (aims to assess the safety of oral immune therapy standard of care):Safety of Oral Immune Therapies for Peanuts, Milk and Eggs | View details › |
| 128 | 2025 | DOH/ADHRTC/2025/2217 | Genomics-related research:Associating UAE-specific genomic variants of neurodegenerative disorders with neuroimaging-derived phenotypes | View details › |
| 129 | 2025 | DOH/ADHRTC/2025/2714 | Multi-center study:A multi-omics program for Next Generation Screening: Focus on Proteomics for CVD risk identification Presented in Meeting#21-2025 on 24-Sep-2025.Decision was: Conditional approval.Additional documents received, shared with reviewer (Dr. Adam & Dr. Khaled) and approved, IS approval on 02-Oct-2025 & Genome Approval(higher authorize) with statement to be included in the approval letter. | View details › |
| 130 | 2025 | DOH/ADHRTC/2026/234 | Data-Driven Vaccine and Infectious Disease Strategy in the UAE: Integrating Health Information Exchanges and AMR Surveillance to Identify Circulating Vaccine-Preventable Pathogens and Inform Public Health Interventions | View details › |
| 131 | 2025 | DOH/ADHRTC/2026/67 | Multi-center, Clinical Trial, Pharmaceutical sponsored & Processing of medical data outside UAE for research purpose:IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 TreatmentPresented in Meeting#22-2025 on 08-Oct-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Abdishakur) and approved, IS approval on 27-Oct-2025. | View details › |
| 132 | 2025 | DOH/ADHRTC/2025/468 | Unveiling the Functional Impact of Novel Variants Associated with Inborn Errors of Immunity (IEI) in Families in the United Arab Emirates | View details › |
| 133 | 2025 | DOH/ADHRTC/2025/2616 | Public Health Research (Mixed Method) on Health Care Practitioners in Abu Dhabi nASSESSING KNOWLEDGE, ATTITUDE AND PRACTICE REGARDING CHILD MALTREATMENTAMONG HEALTH CARE PROVIDERS IN THE EMIRATES OF ABU DHABI: A MIXED METHOD STUDYPresented in Meeting#22-2025 on 08-Oct-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Abdishakur) and approved, IS approval on 03-Nov-2025. | View details › |
| 134 | 2025 | DOH/ADHRTC/2025/915 | Artificial Intelligence-Powered and Data-Driven Type II Diabetes Prediction in the United Arab Emirate | View details › |
| 135 | 2025 | DOH/ADHRTC/2025/2598 | Genomics-related research:“Next Generation Sequencing Analysis and Profiling for Solid and Hematological Malignancies in Patients of Arab Descent”Presented in Meeting#23-2025 on 22-Oct-2025.Decision was: Pending Additional documents received, shared with reviewer (Dr. Adam & Dr. Saleh) and approved & IS approved. | View details › |
| 136 | 2025 | DOH/ADHRTC/2025/2936 | Retrospective-Prospective Survey Study:Assessment of factors impacting uptake of risk reducing preventative options among high-risk patients tested positive for germline mutation in HBOC genes: A single Centre experience.Presented in Meeting#23-2025 on 22-Oct-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Rene) and approved & IS approved. | View details › |
| 137 | 2025 | DOH/ADHRTC2026/500 | Single-centre prospective cohort Study:Prediction of Embryo Aneuploidy using Non-invasive Morphokinetics and Culture Media Readouts | View details › |
| 138 | 2025 | DOH/ADHRTC/2025/2597 | Multi-center study:Global Stroke Outcomes: An international prospective observational study of management and outcomes in acute ischemic strokes caused by large vessel occlusion Presented in Meeting#23-2025 on 22-Oct-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Rene & Dr. Saleh) and approved & IS approval on 07-Nov-2025. | View details › |
| 139 | 2025 | DOH/ADHRTC/2025/2595 | Clinical Trial study:“Hyper fractionated radiation therapy versus concurrent chemo-radiation for Head and neck Cancer: A phase III randomized control trial”Presented in Meeting#23-2025 on 22-Oct-2025.Decision was: Conditional Approval Additional documents received, shared with reviewer (Dr. Abdishakur & Dr. Shahrukh) and approved & IS approved. | View details › |
| 140 | 2025 | DOH/ADHRTC/2025/2508 | Multi-center, Clinical Trial (Phase III), Pharmaceutical sponsored, Research with genetic material, Processing of medical data outside UAE for research purposes & Research that carries significant or potential risk to human subjects (patients) Study:A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa | View details › |
| 141 | 2025 | — | Multi-center, Clinical Trial, Pharmaceutical sponsored & Processing of medical data outside UAE for research purpose Study:A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma | View details › |
| 142 | 2025 | DOH/ADHRTC/2026/274 | Descriptive correlational research:The Relationship Between Nurses' Self-Efficacy and Their Performance During Mock Code Pink Drills | View details › |
| 143 | 2025 | DOH/ADHRTC/2025/2852 | Multi-center, Clinical Trial (Phase IV), Pharmaceutical sponsored, Processing of medical data outside UAE for research purposes:PERIS: Prospective multi-country, real-world, multi-arm study of treatment PErsistence with RISankizumab in Psoriatic ArthritisPresented in Meeting#23-2025 on 22-OCT-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Milos) and approved & IS approved | View details › |
| 144 | 2025 | DOH/ADHRTC/2026/491 | Retrospective Chart Review (Prospective study on data collected via the Emirati Genome Program):Population-Scale Pharmacogenomics for Preventive and Precision Healthcare in Emirati Citizens/residents: Insights into Real-World Effectiveness, Safety Outcomes, and Policy Implications from 160,000 PGx Reports in the Emirati Genome Program. | View details › |
| 145 | 2025 | DOH/ADHRTC/2026/249 | UAEU undergraduate senior project (Applied Research / Development of AI-Powered Medical Diagnostic Support Tools):AI-Based Real-Time Absence Seizure Detection in Children Using Classroom Video Surveillance | View details › |
| 146 | 2025 | DOH/ADHRTC/2025/2850 | Clinical Trial study (Phase III):Comparison of Semaglutide versus Tirzepatide in fatty liver disease in type 2 diabetic patients using liver elastographyPresented in Meeting#24-2025 on 05-Nov-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Shahrukh) and approved, IS approved & Genome approved | View details › |
| 147 | 2025 | DOH/ADHRTC/2025/825 | Analyzing exceptional long-term survival in patients with poor prognosis solid tumors – retrospective, exploratory, multi-center, translational, 3 cohorts case control (1:1) matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard) survival. | View details › |
| 148 | 2025 | DOH/ADHRTC/2026/502 | Multi-center study A registry – based, retrospective, cohort multi-center study:MS ApplicationAI-Driven Neuroimaging for Differentiating MS from NMOSD and Monitoring Treatment Response in NMOSD | View details › |
| 149 | 2025 | ADHRTC/2026/7 | REAL-WORLD DATA/REAL-WORLD EVIDENCE-BASED CLINICAL RESEARCH:Prospective Real-World Study Protocol for RSV prophylaxis in Abu Dhabi | View details › |
| 150 | 2025 | DOH/ADHRTC/2025/2903 | Descriptive-analytical social study (Health Related Survey):Social and psychological factors influencing emotional divorcePresented in Meeting#24-2025 on 05-Nov-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Shahrukh) and approved & IS approved. | View details › |
| 151 | 2025 | DOH/ADHRTC/2025/2849 | Multi-center study:Impact of Integrative Oncology Care on Clinical Outcomes, Toxicity, and GPCR-Associated Biomarkers: A Retrospective Cohort Study. | View details › |
| 152 | 2025 | DOH/ADHRTC/2025/2849 | Multi-center study:Impact of Integrative Oncology Care on Clinical Outcomes, Toxicity, and GPCR-Associated Biomarkers: A Retrospective Cohort Study.Presented in Meeting#24-2025 on 05-Nov-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Adam) and approved & IS approved. | View details › |
| 153 | 2025 | ADHRTC/2025/74 | Prospective validation of cancer screening tools:Study Protocol: Real World Study for Multi Cancer Early Detection (MCED) in the UAE | View details › |
| 154 | 2025 | DOH/ADHRTC/2025/2712 | Multi-center, Clinical Trial, Pharmaceutical sponsored & Processing of medical data outside UAE for research purpose Study:Cadisegliatin as Adjunctive Therapy in Type 2 Diabetes: A 52-Week Double-Blind, Randomized, Placebo-Controlled Phase 2 Study (CATT2) | View details › |
| 155 | 2025 | DOH/ADHRTC/2025/2711 | Retrospective Chart Review Study:Orthopedic Manifestations in Patients with Methylmalonic Acidemia: A Retrospective Cohort Study from a Tertiary Hospital in the United Arab Emirates. | View details › |
| 156 | 2025 | DOH/ADHRTC/2025/2944 | Retrospective observational study:A Retrospective Study Investigating the Real-World Treatment Patterns and Clinical Profiles of Patients Diagnosed with Chronic Urticaria (CU) and Chronic Idiopathic Urticaria (CIU) in the Malaffi Database, Abu Dhabi. | View details › |
| 157 | 2025 | DOH/ADHRTC/2026/160 | Multi-center study:Transcatheter Aortic Valve Replacement using Sapien 3 Ultra Resilia Valve: Investigator-initiated, observational Registry in Gulf region | View details › |
| 158 | 2025 | DOH/ADHRTC/2025/2902 | Neuroimaging data analysis for Epilepsy patients: Studying Epilepsy Using Non-Invasive Brain Imaging (EEG, MEG, fMRI, EEG compatible fMRI)Presented in Meeting#25-2025 on 24-Nov-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Saleh) and approved & IS approved. | View details › |
| 159 | 2025 | ADHRTC/2026/1 | pharmaceutical sponsor, Multi Centers, Device Study:Pilot Study on Self-Collection Brush for Cervical Cancer Screening in Abu Dhabi | View details › |
| 160 | 2025 | DOH/ADHRTC/2025/2927 | Research with genetic material Study:MS ApplicationGene Therapy Targeting USP18 to Enhance Type I Interferon Responsiveness in Multiple Sclerosis: A Preclinical Proof-of-Concept Study | View details › |
| 161 | 2025 | DOH/ADHRTC/2026/233 | Multi-center study, Developing Precision Neuroprotective Therapy for MS Using Patient-Derived Brain OrganoidsMS ApplicationDeveloping Precision Neuroprotective Therapy for MS Using Patient-Derived Brain Organoids | View details › |
| 162 | 2025 | DOH/ADHRTC/2026/238 | Multi-center study, Preclinical study:MS ApplicationEmirati-specific MS-on-a-chip to treat the disease using a novel target | View details › |
| 163 | 2025 | DOH/ADHRTC/2025/1026 | DIRECT ORAL ANTICOAGULANTS FOR THE TREATMENT OF CEREBRAL VENOUS THROMBOSIS: AN INTERNATIONAL PHASE IV STUDY | View details › |
| 164 | 2025 | DOH/ADHRTC/2025/2926 | Data Analysis, Malafi Data:Estimating Low Birth Weight and Their Determinants Using Electronic Health Records in Abu Dhabi (2020–2025) | View details › |
| 165 | 2025 | DOH/ADHRTC/2025/2901 | Research with genetic material Study:Working Memory and Women’s Health | View details › |
| 166 | 2025 | DOH/ADHRTC/2026/529 | Multi Centers, Cross-Sectional Observational Surveypharmacy Professional’s Readiness and Barriers to Implementing Antimicrobial Stewardship in Non Inpatient Settings: Implications for Health Policy Development in the Abu Dhabi Emirate – A Cross-Sectional Survey | View details › |
| 167 | 2025 | DOH/ADHRTC/2025/2947 | Secondary data analysis Study:The Association Between HbA1c Levels and the Incidence of Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Retrospective Cohort Study From Abu Dhabi Population | View details › |
| 168 | 2025 | DOH/ADHRTC/2026/64 | Population Health Study:Understanding sleep and meal timing in Ramadan Observers | View details › |
| 169 | 2025 | DOH/ADHRTC/2026/343 | Retrospective Cohort Study:ALIGN UAE - Assessing the Implementation of Guideline- Recommended Lipid-Lowering Therapies in Very High-Risk or High-Risk CVD Patients in the UAE | View details › |
| 170 | 2025 | DOH/ADHRTC/2026/407 | Genetic Insights into Chronic Kidney Disease in the Emirati Population: A Whole Genome Sequencing Study | View details › |
| 171 | 2025 | DOH/ADHRTC/2025/2946 | Secondary data analysis Study:Probability of an Obese Person Attaining Normal Body Weight: Retrospective Cohort Study Using Malaffi Electronic Health Records in Abu Dhabi | View details › |
| 172 | 2025 | DOH/ADHRTC/2025/2945 | Multi-center, Research with genetic material & Genomics-related research Study:Emirati Polygenic Risk Score Development and Validation for Thyroid, Prostate, and Colon Cancer Using EGP Genomes and Malaffi Clinical Data | View details › |
| 173 | 2025 | DOH/ADHRTC/2025/350 | The Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection at a Tertiary Care Center in the UAE | View details › |
| 174 | 2025 | DOH/ADHRTC/2025/830 | Optimizing the use of Freestyle libre 2 intermittent continuous glucose monitoring in T2DM management: An open-label, randomized controlled trial. | View details › |
| 175 | 2025 | DOH/ADHRTC/2025/1033 | Ureter-on-chip to monitor biofilm formation and optimize therapy for UTIs | View details › |
| 176 | 2025 | DOH/ADHRTC/2025/824 | Real-World Effectiveness and Safety of Ofatumumab in Patients with Relapsing Multiple Sclerosis: A Retrospective Chart Review of the United Arab Emirates Experience” – COMB157GAE02 | View details › |
| 177 | 2025 | DOH/ADHRTC/2025/1157 | Review of Janus Kinase (JAK) Inhibitors efficacy and safety in the Treatment of Rheumatoid Arthritis and Some Autoimmune Skin Diseases in a tertiary hospital in UAE | View details › |
| 178 | 2025 | DOH/ADHRTC/2025/1169 | Brain malformations: Description and correlation of clinical phenotype, neuroimaging findings and genomic/genetic findings in pediatric patients in Tawam Hospital, Al Ain, United Arab Emirates. | View details › |
| 179 | 2025 | DOH/ADHRTC/2025/1868 | Electrophysiology of Candida Auris for Prevention and Diagnoses (EsCAPaDe) | View details › |
| 180 | 2025 | DOH/ADHRTC/2026/404 | Survey-Based / Qualitative Study:Understanding Medical Travel Experience among United Arab Emirates Oncology Patients: A Qualitative Study | View details › |
| 181 | 2025 | DOH/ADHRTC/2026/345 | Clinical Trial study; (Phase III) & Multi-center:Thymosin-α1 for Unexplained Recurrent Pregnancy Loss (uRPL): A Randomized, Double-Blind, Placebo-Controlled Superiority Trial | View details › |
| 182 | 2025 | DOH/ADHRTC/2025/828 | Prospective Observational Study to Assess Effectiveness and Safety of Tralokinumab in Adolescent Patients with Atopic Dermatitis in United Arab Emirates. | View details › |
| 183 | 2025 | DOH/ADHRTC/2025/1035 | Multi-center study: An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment | View details › |
| 184 | 2025 | DOH/ADHRTC/2025/1150 | Assessing the readiness of Oxford Nanopore sequencing for clinical genomics applications | View details › |
| 185 | 2025 | DOH/ADHRTC/2025/1136 | Assessing short-term treatment satisfaction and Quality of Life in patients with Hidradenitis Suppurativa initiated on Secukinumab in routine clinical practice in the United Arab Emirates: ILLUMINATE-HS, a prospective patient survey Dr. Ahmed Al Dhaheri-Cleveland Clinic Abu Dhabi | View details › |
| 186 | 2025 | DOH/ADHRTC/2025/1032 | Understanding the Genetic Component of Inherited Retinal Degenerations and Nonsyndromic Hearing Loss in the Emirati Population | View details › |
| 187 | 2025 | DOH/ADHRTC/2025/1889 | Prospective Study of Antimicrobial Resistance in Chronic Lung Disease (PRESIDE) | View details › |
| 188 | 2025 | DOH/ADHRTC/2025/1028 | AI Based Oropharynx Abnormalities Detection | View details › |
| 189 | 2025 | DOH/ADHRTC/2025/872 | Research that carries significant or potential risk to human subjects (patients) & Clinical Trial study: UAE-PRIME1: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices | View details › |
| 190 | 2025 | DOH/ADHRTC/2025/685 | Retrospective case control study for the development of an Artificial Intelligence (AI)- based tool of lesion detection based on Magnetic Resonance Imaging (MRI) and clinical variables for early diagnosis of axial Spondyloarthritis (axSpA) | View details › |
| 191 | 2025 | DOH/ADHRTC/2025/1874 | PREDICT Study: Application of Avantect Pancreatic Cancer Test in High-Risk Populations | View details › |
| 192 | 2025 | DOH/ADHRTC/2025/1461 | Effect of Sex Hormone Signalling on Ageing of Dermal, Vaginal and Placental Fibroblasts. | View details › |
| 193 | 2025 | DOH/ADHRTC/2025/2285 | A Study to Evaluate the Rejuvenation of the Ovary Using Exosomes Derived from Human Placenta Mesenchymal Stem Cells (ROSE-2) | View details › |
| 194 | 2025 | DOH/ADHRTC/2025/675 | Evidence-based Policies to Improve the Uptake of Dietetics Services in HealthCare Settings across the United Arab Emirates. | View details › |
| 195 | 2025 | DOH/ADHRTC/2025/978 | A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study to Evaluate the Safety, Efficacy and Tolerability of Ofirnoflast (HT-6184) and Semaglutide in Obese or Overweight Participants with Type 2 Diabetes Mellitus (T2DM) | View details › |
| 196 | 2025 | DOH/ADHRTC/2025/1558 | Detection of Mental Fatigue State Using EEG/ECG Signals | View details › |
| 197 | 2025 | DOH/ADHRTC/2025/1154 | Impact of Pharmacist Clinical Recommendations on Proton Pump Inhibitor Deprescribing: A Retrospective Study in a Long-Term Care Facilit | View details › |
| 198 | 2025 | DOH/ADHRTC/2025/1463 | The Emirati Pediatric Rheumatology Investigators (EPRI) Registry for Juvenile Idiopathic Arthritis (JIA) | View details › |
| 199 | 2025 | DOH/ADHRTC/2025/2509 | Mixed Method Study with pre-post design:An observational study to evaluate the process and impact outcomes of implementing derived measures to recognize residual symptoms of major depressive disorder. | View details › |
| 200 | 2025 | DOH/ADHRTC/2025/437 | Precision Medicine in Diagnosis and Treatment of Type 2 Diabetes Mellitus in the United Arab Emirates | View details › |
| 201 | 2025 | DOH/ADHRTC/2025/1999 | Randomized Control Study:Structured Help for Families in Illness and Focused Assistance in Palliative Care: A Randomized Controlled Trial (SHIFA-PC-RCT)Presented in Meeting#10-2025 on 23-Apr- 2025.Decision was: Pending.Additional documents received, shared with reviewer (Dr. Adam & Dr. Khaled) and approved & IS approval. | View details › |
| 202 | 2025 | DOH/ADHRTC/2025/1155 | Enabling GWAS and PRS Tools for the Emirati Genome Program: Empowering Disease Management and Drug Discovery | View details › |
| 203 | 2025 | DOH/ADHRTC/2025/1992 | Multi-center & Clinical Trial study:A multi-factorial, multi-arm, multi-stage, randomized, global Adaptive platform trial for stroke (ACT-GLOBAL) Domain-Specific Appendix BLOOD PRESSURE DOMAIN (ENCHANTED/MT)Presented in Meeting#11-2025 on 07-May- 2025.Decision was: Pending.Additional documents received, shared with reviewer (Dr. Rene) and approved & IS approval on 14-8-2025. | View details › |
| 204 | 2025 | DOH/ADHRTC/2025/2407 | Genomics-related research Study:My Genome- Finding Heterozygous Familial Hypercholesterolemia –Common genetic disorder in EmiratisPresented in Meeting#11-2025 on 07-May-2025.Decision was: Conditionally approved.Additional documents received, shared with the reviewers (Dr. Saleh) and approved, IS approval on 30-Jul-2025 and Genome clearance on 13-Oct-2025. | View details › |
| 205 | 2025 | DOH/ADHRTC/2025/1460 | Renal Outcomes and Genetic Profiling in aHUS children: A Retrospective, Multicentre Study in Abu Dhabi | View details › |
| 206 | 2025 | DOH/ADHRTC/2025/921 | Diagnosis of rotator cuff tear, calcification and angle measurement in X-ray using Deep Learning Algorithm. | View details › |
| 207 | 2025 | DOH/ADHRTC/2025/1175 | Targeted Genetic Screening of the CYP21A Gene to Unveil the Landscape of Congenital Adrenal Hyperplasia in the Emirati Population Using Next-Generation Sequencing | View details › |
| 208 | 2025 | DOH/ADHRTC/2025/1117 | Clonal Hematopoiesis of Indeterminate Potential (CHIP) Among Emirati Cancer Patients: A Pilot Study. | View details › |
| 209 | 2025 | DOH/ADHRTC/2025/365 | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partialreplicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | View details › |
| 210 | 2025 | DOH/ADHRTC/2025/832 | Predictive, preventative, personalized and participatory (P4) medical practices can positively impact the health status of an individual with inflammatory bowel disease. | View details › |
| 211 | 2025 | DOH/ADHRTC/2025/477 | Assessment of depression and anxiety among cancer patients in UAE: A cross-sectional study | View details › |
| 212 | 2025 | DOH/ADHRTC/2025/478 | A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone with Background Dapagliflozin in Subjects with Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM) | View details › |
| 213 | 2025 | DOH/ADHRTC/2025/549 | Interest of the salivary signature of endometriosis in the healthcare pathway of adolescent – The ADOmiARN study | View details › |
| 214 | 2025 | DOH/ADHRTC/2025/672 | Clinical and demographic profile of Intrathecal Baclofen Pump patients in UAE | View details › |
| 215 | 2025 | DOH/ADHRTC/2025/576 | Epidemiology of Myasthenia Gravis in the United Arab of Emirates | View details › |
| 216 | 2025 | DOH/ADHRTC/2025/475 | Comparative Analysis of Percutaneous Coronary Intervention versus Coronary Artery Bypass Grafting Versus Medical Therapy for Chronic Total Occlusion: Insights from the Gulf Chronic Total Occlusion (G-CTO) Registry | View details › |
| 217 | 2025 | DOH/ADHRTC/2025/888 | Multi-center & Pharmaceutical sponsored study: Real-World Effectiveness and Safety of Ofatumumab in patients with Relapsing Multiple Sclerosis: The United Arab Emirates Experience | View details › |
| 218 | 2025 | DOH/ADHRTC/2025/925 | Multi-center & Pharmaceutical sponsored study: Real-World Effectiveness and Safety of Ofatumumab in patients with Relapsing Multiple Sclerosis: The United Arab Emirates Experience | View details › |
| 219 | 2025 | DOH/ADHRTC/2025/926 | Multi-center & Pharmaceutical sponsored study: Real-World Effectiveness and Safety of Ofatumumab in patients with Relapsing Multiple Sclerosis: The United Arab Emirates Experience | View details › |
| 220 | 2025 | DOH/ADHRTC/2025/1255 | A Phase III Adjuvant Trial Evaluating the Additionof Adjuvant Chemotherapy to Ovarian FunctionSuppression plus Endocrine Therapy inPremenopausal Patients with pN0-1, ERPositive/HER2-Negative Breast Cancer and anOncotype Recurrence Score ≤ 25 (OFSET) | View details › |
| 221 | 2025 | DOH/ADHRTC/2025/1134 | Prognostic and Predictive role of tumor associated antigen NY-ESO-1 and immune modulatory biomarkers in Triple negative breast cancer patients in Abu Dhabi UAE | View details › |
| 222 | 2025 | DOH/ADHRTC/2025/670 | Searching for recessive regulatory mutations that underlie human diabetes patients in the UAE. | View details › |
| 223 | 2025 | DOH/ADHRTC/2025/349 | Real-World Insights into Incidence, Associated Factors, and Recommendations on a Monitoring Plan for Immunotherapy-related Thyroid Toxicity at a Tertiary Care Hospital in the UAE: A Retrospective Observational Cohort Study | View details › |
| 224 | 2025 | DOH/ADHRTC/2025/1941 | Investigating Salivary Oxytocin Levels in Psychiatric Disorders: Exploring Biomarker Potential and Clinical Implications Across Depression, Anxiety Disorders, Autism Spectrum Disorders, and Schizophrenia. | View details › |
| 225 | 2025 | DOH/ADHRTC/2025/1220 | A Randomized, Double-Blind, Placebo-ControlledMulticenter Phase 2 Study to Evaluate the Safety,Efficacy and Tolerability of Ofirnoflast (HT-6184)and Semaglutide in Obese or OverweightParticipants with Type 2 Diabetes Mellitus (T2DM) | View details › |
| 226 | 2025 | DOH/ADHRTC/2025/1217 | A Phase 3a, open-label, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational varicella vaccine and Priorix compared with subcutaneous administration of Varivax and Priorix, when given as a first dose to healthy children 12 to 15 months of age | View details › |
| 227 | 2025 | DOH/ADHRTC/2025/1218 | A Phase 3a, open-label, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational varicella vaccine and Priorix compared with subcutaneous administration of Varivax and Priorix, when given as a first dose to healthy children 12 to 15 months of age | View details › |
| 228 | 2025 | DOH/ADHRTC/2025/1219 | A Phase 3a, open-label, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational varicella vaccine and Priorix compared with subcutaneous administration of Varivax and Priorix, when given as a first dose to healthy children 12 to 15 months of age | View details › |
| 229 | 2025 | DOH/ADHRTC/2025/1317 | Investigating the Impact of Ionized Alkaline Wateron Athletic Performance & Gut Health in SportAthletes: A Within-Subjects Design Study | View details › |
| 230 | 2025 | DOH/ADHRTC/2025/2002 | Multi-center, Clinical Trial, Pharmaceutical sponsored, Research with genetic material, Processing of medical data outside UAE for research purpose Study & Research that carries significant or potential risk to human subjects (patients):A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) Presented in Meeting#12-2025 on 22-May- 2025.Decision was: Pending.Additional documents received, shared with reviewer (Dr. Saleh & Dr. Rene) and approved, IS approval on 25-8-2025 & Genome Approval with statement. | View details › |
| 231 | 2025 | DOH/ADHRTC/2025/1998 | Multi-center, Clinical Trial, Pharmaceutical sponsored, Research with genetic material, Processing of medical data outside UAE for research purpose Study & Research that carries significant or potential risk to human subjects (patients):A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) Presented in Meeting#12-2025 on 22-May- 2025.Decision was: Pending.Additional documents received, shared with reviewer (Dr. Saleh & Dr. Rene) and approved, IS approval on 25-8-2025 & Genome Approval with statement. | View details › |
| 232 | 2025 | DOH/ADHRTC/2025/2001 | Multi-center, Clinical Trial, Pharmaceutical sponsored, Research with genetic material, Processing of medical data outside UAE for research purpose Study & Research that carries significant or potential risk to human subjects (patients):A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) Presented in Meeting#12-2025 on 22-May- 2025.Decision was: Pending.Additional documents received, shared with reviewer (Dr. Saleh & Dr. Rene) and approved, IS approval on 25-8-2025 & Genome Approval with statement. | View details › |
| 233 | 2025 | DOH/ADHRTC/2025/1464 | A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients with Diffuse Large B-Cell Lymphoma in the MEA Region – DOMAIN Study | View details › |
| 234 | 2025 | DOH/ADHRTC/2025/1465 | A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients with Diffuse Large B-Cell Lymphoma in the MEA Region – DOMAIN Study | View details › |
| 235 | 2025 | DOH/ADHRTC/2025/1608 | Creation of a virtual human twin as a tool forbreast cancer screening (detection aid) | View details › |
| 236 | 2025 | DOH/ADHRTC/2025/1898 | Exploring Factors Influencing Turnover Among Emirati Nurses: A Mixed-Methods Study | View details › |
| 237 | 2025 | DOH/ADHRTC/2025/1453 | Impact of HiPSC-Derived Ovarian Support Cell Co-Culture (OSC-IVM) (Fertilo) on enhancing Immature Oocyte competency in Assisted Reproductive Technology | View details › |
| 238 | 2025 | DOH/ADHRTC/2025/1919 | Sanofi Genzyme Rare Diseases Registry Program | View details › |
| 239 | 2025 | DOH/ADHRTC/2025/1460 | Renal Outcomes and Genetic Profiling in aHUS children: A Retrospective, Multicentre Study in Abu Dhabi | View details › |
| 240 | 2025 | ADHRTC/2026/11 | Processing of medical data outside UAE for research purpose Study:Associations between heat and health: a retrospective study of emergency admissions and mortality in the Emirate of Abu Dhabi. | View details › |
| 241 | 2025 | DOH/ADHRTC/2025/1598 | Association Between Nutritional Status and the Risk of Sarcopenia among older adults in UAE: A Hospital-based Study | View details › |
| 242 | 2025 | DOH/ADHRTC/2025/1597 | Maternal and Perinatal Outcomes Following Trauma in Pregnancy: A 10-Year Retrospective Analysis | View details › |
| 243 | 2025 | DOH/ADHRTC/2025/559 | A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. | View details › |
| 244 | 2025 | DOH/ADHRTC/2025/1746 | CONSTELLATION: A multi-Center, nOn-iNterventional Study of Treatment persistence and Efficacy of guseLkumab in uLcerative colitis & crohn’s diseAse paTIents in real-wOrld practice in the UNited Arab Emirates. | View details › |
| 245 | 2025 | DOH/ADHRTC/2025/1745 | CONSTELLATION: A multi-Center, nOn-iNterventional Study of Treatment persistence and Efficacy of guseLkumab in uLcerative colitis & crohn’s diseAse paTIents in real-wOrld practice in the UNited Arab Emirates. | View details › |
| 246 | 2025 | DOH/ADHRTC/2025/1744 | CONSTELLATION: A multi-Center, nOn-iNterventional Study of Treatment persistence and Efficacy of guseLkumab in uLcerative colitis & crohn’s diseAse paTIents in real-wOrld practice in the UNited Arab Emirates. | View details › |
| 247 | 2025 | DOH/ADHRTC/2025/2108 | UAE Spondyloarthritis Registry | View details › |
| 248 | 2025 | ADHRTC/2025/49 | Public Health Priority Research on Communicable and Non-Communicable Diseases: A Multi-Dimensional Approach Utilizing EMR and Genomic Data | View details › |
| 249 | 2025 | DOH/ADHRTC/2025/2128 | A Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who are Naïve to Targeted Therapies | View details › |
| 250 | 2025 | DOH/ADHRTC/2025/2130 | A Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who are Naïve to Targeted Therapies | View details › |
| 251 | 2025 | DOH/ADHRTC/2025/2132 | A Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who are Naïve to Targeted Therapies | View details › |
| 252 | 2025 | DOH/ADHRTC/2025/2134 | A Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who are Naïve to Targeted Therapies | View details › |
| 253 | 2025 | DOH/ADHRTC/2025/1897 DOH_ADHRTC_2025_1896 | Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies | View details › |
| 254 | 2025 | DOH/ADHRTC/2025/2212 | Epidemiological modelling of infectious diseases for decision making and interventions response | View details › |
| 255 | 2025 | ADHRTC/2025/57 | Epidemiological Study on Mental Illness in Abu Dhabi: Prevalence, Incidence, and Impact of Stigma | View details › |
| 256 | 2025 | DOH/ADHRTC/2025/2104 | Epidemiological Study on Mental Illness in Abu Dhabi: Prevalence, Incidence, and Impact of Stigma | View details › |
| 257 | 2025 | DOH/ADHRTC/2025/2033 | The impact of Cultural Diversity on Radiographer Resilience, a Case Study within a UAE Healthcare Organisation. | View details › |
| 258 | 2025 | DOH/ADHRTC/2025/2207 | Multi-center, Clinical Trial (Phase III) & Pharmaceutical sponsored study: Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study) | View details › |
| 259 | 2025 | DOH/ADHRTC/2025/2216 | Multi-center, Clinical Trial (Phase III) & Pharmaceutical sponsored study: Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study) | View details › |
| 260 | 2025 | DOH/ADHRTC/2025/2214 | Multi-center, Clinical Trial (Phase III) & Pharmaceutical sponsored study: Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study) | View details › |
| 261 | 2025 | ADHRTC/2025/55 | Retrospective Research with Malaffi/Claims/ Registries:Prevalence and Risk Factors for Female Infertility in Abu Dhabi Population (2013-2025): A Retrospective Study | View details › |
| 262 | 2025 | DOH/ADHRTC/2025/1549 | A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-THROUGH STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH RO7790121 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | View details › |
| 263 | 2025 | DOH/ADHRTC/2025/1550 | A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-THROUGH STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH RO7790121 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | View details › |
| 264 | 2025 | DOH/ADHRTC/2025/1551 | A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-THROUGH STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH RO7790121 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | View details › |
| 265 | 2025 | DOH/ADHRTC/2025/2713 | Multi-center, Pharmaceutical sponsored & Processing of medical data outside UAE for research purpose Study:Evaluation of salivary RNA in subjects scheduled for surgery for a gynecologic pathologyPresented in Meeting#12-2025 on 22-May-2025.Decision was: Conditional approval.additional documents received, shared with reviewer (Dr. Adam & Dr. Khaled) and approved, IS approval on 02-Oct-2025 & Genome Approval(higher authorize) with statement to be included in the approval letter. | View details › |
| 266 | 2025 | DOH/ADHRTC/2025/2215 | Multi-center, Pharmaceutical sponsored & Processing of medical data outside UAE for research purpose Study:REal-World Application of Luspatercept in Adults with Transfusion-Dependent beta-Thalassemia in the Middle East (RELATE): A non-interventional retrospective and prospective observational study | View details › |
| 267 | 2025 | DOH/ADHRTC/2025/2218 | Multi-center, Pharmaceutical sponsored & Processing of medical data outside UAE for research purpose Study:REal-World Application of Luspatercept in Adults with Transfusion-Dependent beta-Thalassemia in the Middle East (RELATE): A non-interventional retrospective and prospective observational study | View details › |
| 268 | 2025 | DOH/ADHRTC/2025/2599 | Multi-center & Pharmaceutical sponsored study Use of the clinical decision support tool (CDST) in predicting probability of response to vedolizumab in Middle Eastern Crohn’s Disease patients: the ME-VOICE study (Middle East Vedolizumab Outcomes probability In CDST Evaluation).Presented in Meeting#22-2025 on 08-Oct-2025.Decision was: Conditional Approval Additional documents received, shared with reviewer (Dr. Milos) and approved, IS approval on 07-Nov-2025. | View details › |
| 269 | 2025 | DOH/ADHRTC/2025/2596 | Multi-center & Pharmaceutical sponsored study Use of the clinical decision support tool (CDST) in predicting probability of response to vedolizumab in Middle Eastern Crohn’s Disease patients: the ME-VOICE study (Middle East Vedolizumab Outcomes probability In CDST Evaluation).Presented in Meeting#22-2025 on 08-Oct-2025.Decision was: Conditional Approval Additional documents received, shared with reviewer (Dr. Milos) and approved, IS approval on 07-Nov-2025. | View details › |
| 270 | 2025 | DOH/ADHRTC/2026/61 | Decoding Doctor–Patient Communication in Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Cross-Sectional Patient Survey in the United Arab Emirates (BC INFORM) | View details › |
| 271 | 2025 | DOH/ADHRTC/2026/62 | Decoding Doctor–Patient Communication in Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Cross-Sectional Patient Survey in the United Arab Emirates (BC INFORM) | View details › |
| 272 | 2025 | DOH/ADHRTC/2026/63 | Decoding Doctor–Patient Communication in Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Cross-Sectional Patient Survey in the United Arab Emirates (BC INFORM) | View details › |
| 273 | 2025 | DOH/ADHRTC/2025/827 | Characteristics and Outcomes of Pediatric Critical Pertussis in Arab Gulf Region: A Multicenter Cohort Study | View details › |
| 274 | 2025 | DOH/ADHRTC/2025/2848 | Multi-center, Clinical Trial, Pharmaceutical sponsored study & Processing of medical data outside UAE for research purpose:A Phase 2a, Open-label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Select Autoimmune DiseasesPresented in Meeting#24-2025 on 05-Nov-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Khaled & Dr. Milos) and approved & IS approved. | View details › |
| 275 | 2025 | DOH/ADHRTC/2025/2851 | Multi-center, Clinical Trial, Pharmaceutical sponsored study & Processing of medical data outside UAE for research purpose:A Phase 2a, Open-label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Select Autoimmune DiseasesPresented in Meeting#24-2025 on 05-Nov-2025.Decision was: Conditional ApprovalAdditional documents received, shared with reviewer (Dr. Khaled & Dr. Milos) and approved & IS approved. | View details › |
| 276 | 2025 | DOH/ADHRTC/2025/822 | Analyzing exceptional long-term survival in patients with poor prognosis solid tumors – retrospective, exploratory, multi-center, translational, 3 cohorts case control (1:1) matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard) survival. | View details › |
| 277 | 2025 | DOH/ADHRTC/2026/65 | Multi-center, Clinical Trial, Pharmaceutical sponsored & Processing of medical data outside UAE for research purpose Study:PERIS: Prospective multi-country, real-world, multi-arm study of treatment PErsistence with RISankizumab in Psoriatic Arthritis | View details › |
| 278 | 2025 | DOH/ADHRTC/2025/469 | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects with Moderately to Severely Active Crohn's Disease. | View details › |
| 279 | 2025 | DOH/ADHRTC/2025/686 | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects with Moderately to Severely Active Crohn's Disease. | View details › |
| 280 | 2025 | DOH/ADHRTC/2025/471 | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects with Moderately to Severely Active Crohn's Disease. | View details › |
| 281 | 2025 | DOH/ADHRTC/2026/528 | Multi-center study:Towards Game-Based Automated Screening for Language Disorder | View details › |
| 282 | 2025 | DOH/ADHRTC/2025/1335 | Evaluation of an Artificial Intelligence-FacilitatedSperm Selection Tool for Use in AssistedReproduction | View details › |
| 283 | 2025 | DOH/ADHRTC/2025/1034 | The month of birth and the risk of MS in the middle east region. | View details › |
| 284 | 2025 | DOH/ADHRTC/2025/1158 | CORNERSTONE: A Prospective Observational Study of Atogepant Effectiveness in Routine Clinical Practice | View details › |
| 285 | 2025 | DOH/ADHRTC/2025/780 | A One-Health genomics approach to unveil the evolutionary mechanisms driving the dissemination and spread of Antimicrobial Resistance in the UAE | View details › |
| 286 | 2025 | DOH/ADHRTC/2025/1336 | Liquid biopsy: a new era for diagnosis ofMetabolic dysfunction associated fatty liverdisease (MAFLD) based on whole transcriptomeand profiling of plasma microRNAs in Three ArabCountries | View details › |
| 287 | 2025 | DOH/ADHRTC/2025/669 | Major Vascular Injuries and Outcomes in the United Arab Emirates | View details › |
| 288 | 2025 | DOH/ADHRTC/2025/1135 | Bronchiolitis in infant and children after the surge of COVID-19: predictors of the severity, escalated care and length of stay. | View details › |
| 289 | 2025 | DOH/ADHRTC/2025/1133 | Cushing Disease in the Gulf Region: Multicentre Review of the Clinical Features, Diagnostic Practices, and Therapeutic Outcomes | View details › |
| 290 | 2025 | DOH/ADHRTC/2025/1169 | Brain malformations: Description and correlation of clinical phenotype, neuroimaging findings and genomic/genetic findings in pediatric patients in Tawam Hospital, Al Ain, United Arab Emirates. | View details › |
| 291 | 2025 | DOH/ADHRTC/2025/1156 | Uncovering Molecular Mechanisms and Pathogenesis in Allergy and Immunological Disorders Among Emiratis | View details › |
| 292 | 2025 | ADHRTC/2026/10 | Retrospective Chart Review (Population based):Consumer Buying Behaviour towards Sales Adjustments: Insights from Abu Dhabi’s SEHHI Initiative in Supermarket and Healthcare Settings | View details › |
| 293 | 2025 | DOH/ADHRTC/2025/812 | CALOR Study: Overweight and Obesity Characteristics, Complications And Comorbidities | View details › |
| 294 | 2025 | DOH/ADHRTC/2025/1118 | A Randomized, Investigator-Blinded, Placebo Controlled Trial to Evaluate the Safety and Efficacy of a Doxorubicin Microneedle Array (D-MNA) for the Treatment of Nodular Basal Cell Carcinoma in Adults. | View details › |
| 295 | 2025 | DOH/ADHRTC/2025/1120 | A Randomized, Investigator-Blinded, Placebo Controlled Trial to Evaluate the Safety and Efficacy of a Doxorubicin Microneedle Array (D-MNA) for the Treatment of Nodular Basal Cell Carcinoma in Adults. | View details › |
| 296 | 2025 | DOH/ADHRTC/2025/1119 | A Randomized, Investigator-Blinded, Placebo Controlled Trial to Evaluate the Safety and Efficacy of a Doxorubicin Microneedle Array (D-MNA) for the Treatment of Nodular Basal Cell Carcinoma in Adults. | View details › |
| 297 | 2025 | DOH/ADHRTC/2025/1373 | Assessing short-term treatment satisfaction andQuality of Life in patients with HidradenitisSuppurativa initiated on Secukinumab in routineclinical practice in the United Arab Emirates:ILLUMINATE-HS, a prospective patient survey | View details › |
| 298 | 2025 | DOH/ADHRTC/2025/916 | Exploring Patient Knowledge and Understanding of SpermCryopreservation among men in the United Arab Emirates | View details › |
| 299 | 2025 | DOH/ADHRTC/2025/1257 | EpiGemaP: UAE’s opportunity to accelerate thecreation of the world’s first and mostcomprehensive epigenetic map of the humangenome | View details › |
| 300 | 2025 | DOH/ADHRTC/2025/1132 | The Erectile Restoration Registry: It MATTERS | View details › |
| 301 | 2025 | ADHRTC/2025/33 | Integrating Hybrid Sequencing and ImmuneProfiling to Uncover Genetic Risk Factors andPathogenesis in Membranous Nephropathy | View details › |
| 302 | 2025 | ADHRTC/2025/19 | Retrospective case-control Study on Sudden Death in Individuals Under 50 years in Abu Dhabi: Investigating Associations with COVID-19 Vaccination, Genetic Predisposition, and Other Risk Factors | View details › |
| 303 | 2025 | DOH/ADHRTC/2025/1027 | Transcranial Alternating Current Stimulation (tACS) Modulation of Brain Networks in Obesity-Related Food Cravings: A Triadic Model Approach | View details › |
| 304 | 2025 | DOH/ADHRTC/2025/1258 | Development and validation of the GlobalAdolescent and Child Physical ActivityQuestionnaire (GAC-PAQ) in Al-Ain, United ArabEmirates | View details › |
| 305 | 2025 | DOH/ADHRTC/2025977 | Completion of a pilot study of the safety and efficacy of robotic-assisted surgery of abdominal and pelvic cavities using an Toumai Endoscopic Single-Port Surgical System (SA-1000) | View details › |
| 306 | 2025 | DOH/ADHRTC/2025/1254 | Development of a Personalized ObesityManagement Approach Integrating PersonalizedMulti-Omics Profiles and Machine LearningAlgorithms: The Abu Dhabi iPOP Obesity Study | View details › |
| 307 | 2025 | DOH/ADHRTC/2025/1130 | Achieving sustainable elderly falls injury prevention in the United Arab Emirates | View details › |
| 308 | 2025 | DOH/ADHRTC/2025/1174 | Transcutaneous electrical nerve stimulation (TENS) for the management of pain in neuropathic patients: A prospective, interventional pilot study comparing the effects of different stimulation frequencies | View details › |
| 309 | 2025 | DOH/ADHRTC/2025/1221 | A Randomized, Double-Blind, Placebo-ControlledMulticenter Phase 2 Study to Evaluate the Safety,Efficacy and Tolerability of Ofirnoflast (HT-6184)and Semaglutide in Obese or Overweight | View details › |
| 310 | 2025 | DOH/ADHRTC/2025/1143 | In Vitro Maturation of Immature OocytesFollowing Nuclear Transfer from Aged to Youngfemale Oocytes: Assessing the Potential forRejuvenated Oocyte Function | View details › |
| 311 | 2025 | DOH/ADHRTC/2025/1462 | Risk-Based Penicillin Allergy Delabeling: Enhancing Antibiotic Stewardship and Safer Prescribing Practices in UAE | View details › |
Last updated: 09 May 2026
For an optimal experience please